Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

newagebios 23 posts  |  Last Activity: Jul 29, 2015 12:53 AM Member since: Mar 30, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • newagebios by newagebios Jul 29, 2015 12:53 AM Flag

    Insmed Incorporated reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. The randomized, double-blind, placebo-controlled phase 2 clinical trial compared ARIKAYCE (590 mg delivered once daily), added to standard of care treatment, versus standard of care treatment plus placebo, in 90 adult patients with treatment resistant NTM lung disease. Eligibility for the study required patients to have been on the American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) guideline therapy for at least six months prior to screening and to continue to have persistently positive mycobacterial cultures.

    The primary efficacy endpoint of the study was a semi-quantitative measurement of the change in mycobacterial density on a seven-point scale from baseline (day one) to the end of the randomized portion of the trial (day 84). ARIKAYCE did not meet the pre-specified level for statistical significance
    //
    /
    //
    Patients receiving ARIKAYCE experienced a greater number of adverse events than those receiving placebo. All adverse events experienced with ARIKAYCE were consistent with those seen in similar patient populations receiving inhaled antibiotics. The most common side effect was laryngeal irritation.

  • newagebios by newagebios Jul 29, 2015 12:26 AM Flag

    Insmed (NASDAQ:INSM) was downgraded by Zacks from a “buy” rating to a “hold” rating in a report released
    In other Insmed news, VP Mark Quigley sold 18,750 shares of the stock in a transaction dated Tuesday, . The stock was sold at an average price of $22.07, for a total transaction of $413,812.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

    Shares of Insmed (NASDAQ:INSM) traded up 2.23% during mid-day trading on Tuesday, hitting $26.58. 230,676 shares of the company’s stock traded hands. Insmed has a 52 week low of $11.25 and a 52 week high of $26.77. The stock’s 50-day moving average is $24.22 and its 200-day moving average is $20.70. The company’s market cap is $1.63 billion.
    Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.49) by $0.06. On average, analysts predict that Insmed will post $-1.96 earnings per share for the current fiscal year.
    A number of other firms have also recently commented on INSM. Analysts at Citigroup Inc.initiated coverage on shares of Insmed in a research note on Tuesday, June 9th. They set a “neutral” rating and a $27.00 price target on the stock. Analys

  • blasedp31 aka fud4 aka jad9000 • May 13, 2013 4:47 PM " 2 years is too long !
    "I'm currently in discussion with the global Stop TB Partnership, advising them how they should redesign
    their various therapeutic regimens now that Arikace is available.When they've finally grasped what they should be doing I'll get in touch with Insmed and give them the benefit of my advice."
    =============================
    Tuberculosis (TB) Treatment
    Can't help but think that Insmed will consider Arikayce will be more helpful than the injectable amikacin for TB patients:

    With appropriate antibiotic treatment, TB can be cured in most people. Successful treatment of TB depends on close cooperation between patients and healthcare providers. Treatment usually involves taking several antibiotic drugs for at least 6 months and sometimes for as long as 12 months.

    Antibiotic Resistance and the Importance of Finishing the TB Medicine

    People who do not take all the required medicines can become sick again and spread TB to others. Additionally, when people do not take all the prescribed medicines or skip times when they are supposed to take them, the TB bacteria evolve to outwit the TB antibiotics. Soon those medicines no longer work against the disease. If this happens, the person now has drug-resistant TB. Additionally, some people with TB do not get better with treatment because their disease is caused by a strain of the TB bacterium that is already resistant to one or more of the standard TB drugs.

    Multidrug-resistant TB (MDR TB) is TB that is resistant to at least two of the best Food and Drug Administration-approved anti-TB drugs, isoniazid and rifampicin. These antibiotics are considered first-line drugs and are the first medicines used to treat all persons with TB disease. Extensively drug-resistant TB (XDR TB) is a relatively rare type of TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs

  • newagebios newagebios Jul 27, 2015 7:00 AM Flag

    Terry "didnt post all weekend , but I did . How come you cant read?
    You are very stupid , You will learn
    New York

  • newagebios by newagebios Jul 20, 2015 4:37 PM Flag

    The GLBT INSM Club was outstanding this weekend !

  • Reply to

    kvnmcdd Thank You

    by alazonner Jul 14, 2015 8:30 AM
    newagebios newagebios Jul 16, 2015 2:40 PM Flag

    INSM GLBT Club was established for our persuasion but all are invited! INSMED SUBJECTS
    Average analyst say $26 is the top! till next years decision
    34 MEMBERS Strong

  • Reply to

    What happens when we finally do get some news?

    by mjmfrompa Jul 15, 2015 12:30 PM
    newagebios newagebios Jul 15, 2015 2:59 PM Flag

    depends if the News is bad or good

    NEWS is great for our club kvncmcdd Thanks for all you do

    Im straight but respect you and your boys

  • so funny.

  • Lets get going
    Price target $17

  • I am 19
    with a bod to kill . I am notlez but respect all so stop writing me.

  • Reply to

    It will be fun as we approach 2017

    by jjkimo Jun 20, 2015 6:36 PM
    newagebios newagebios Jun 21, 2015 8:14 AM Flag

    PING !!!! YOU ARE ITDOBANION HHAND219 MIKE75X5 and JD39SOUZA98,=KVNCMCDD

  • Reply to

    It will be fun as we approach 2017

    by jjkimo Jun 20, 2015 6:36 PM
    newagebios newagebios Jun 20, 2015 11:03 PM Flag

    u r an idiot

  • Reply to

    biowatchdog=blank2thisone =kvncmcdd =

    by newagebios Jun 14, 2015 1:22 PM
    newagebios newagebios Jun 14, 2015 2:13 PM Flag

    Hey Toiletturd ! I am not your "terry". Do you live here around the clock waiting for excitement? Loser!

  • ITDOBANION HHAND219 MIKE75X5 and JD39SOUZA98,= all 1 person

  • Reply to

    Today's trading

    by insmhistorian Jun 3, 2015 10:42 PM
    newagebios newagebios Jun 5, 2015 6:45 AM Flag

    jad9000 , You so need to get a life! Your obsession with terry_insm is obvious. You know nothing about the short interest is one reason. I am not him, but enjoy watching him making you look like a fool over and over. You can not guess in investing, but you are guessing. Have a nice day

    example : On May 1, the stock jumped $1.20 and of course ... "jad9000 • May 1, 2015 " they are short, but they may have covered a million shares"
    terry_insm • May 4, 2015 10:14 AM "guess again Evelyn! (jad9000) .... the short interest is adding, I guarantee it. " ...
    and as the numbers last week showed, they indeed added for that week and the next week, to the tune of 500,000 + shares

  • Reply to

    Question - Now What?

    by insmhistorian Jun 4, 2015 4:45 PM
    newagebios newagebios Jun 5, 2015 6:38 AM Flag

    Reply to Question - Now What? by insmhistorian [portend a bullish trend,]
    Terry NEVER said that. You dont know what you are talking about.

  • jad9000 Do you have a LIFE ? !ANY kind of LIFE ?

  • "jad9000 • Feb 11, 2015 " So, 2016 would be a market of 17,500 at a price of around $50,000 annually or slightly under $900 million. All of the EU would be then be around 35,000 cases at $50,000 annually, or $1.75 billion. Then we add in CF, Japan with their 35,000 cases (40,000 by 2016) and the year after the US market around 35,000 (also 40,000 by 2016). That's quite a few billions of dollars by the end of 2016"

  • Reply to

    anyone see this?

    by justarooki04 Apr 26, 2015 3:24 PM
    newagebios newagebios May 20, 2015 1:14 PM Flag

    OF COURSE INSMED WOULD TAKE 140 YOU DUNASSSS! BUT NOBODY WOULD PAY THAT! ARE YOU
    ********* THAT STUPID? ********* SADLY Y E S

  • Reply to

    anyone see this?

    by justarooki04 Apr 26, 2015 3:24 PM
    newagebios newagebios May 20, 2015 1:13 PM Flag

    ***** i am not your "terry" i will posts your stupid posts one after another till you leave

INSM
27.38+0.28(+1.03%)Aug 3 4:00 PMEDT